Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temsirolimus and Bevacizumab in Advanced Solid Tumors
NCT01010126Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2009
- Primary completion
- Mar 2017
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of temsirolimus, bevacizumab in endometrial cancer (EC), ovarian cancer, hepatocellular carcinoma (HCC), Carcinoid Tumor (CT), Pancreatic neuroendocrine tumor (PanNET), sponsored by National Cancer Institute. Started Sep 2009; status: completed.
02
Drugs
temsirolimusbevacizumab
03
Conditions
endometrial cancer (EC)ovarian cancerhepatocellular carcinoma (HCC)Carcinoid Tumor (CT)Pancreatic neuroendocrine tumor (PanNET)
Beyond the preview
Go deeper on NCT01010126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01010126.